Data & Analytics
Caregivers and patients predict how the use of AI will affect them.
What happens in the world of Facebook cannot be ignored in pharma marketing. It increasingly lives in a world of data that is highly sensitive and must be managed well.
Whether it's data or marketing dollars, there should be no surprises when you partner with a company.
The Food and Drug Administration regulates more than a third of the U.S. economy. And its new commissioner, Scott Gottlieb, is trying to shake up how it does so.
In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.
Four data aces share their backgrounds, inspirations, and guiding philosophies
As researchers and analysts, we interact with a wide array of market research pros in the health and wellness space.
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
US bank JPMorgan Chase has returned to advertising on YouTube only after developing its own algorithm that ensures its ads are not placed around questionable content.
New research suggests that the oft-cited $2.6 billion estimate for bringing a drug to market is significantly overstated.
Participants in this roundtable explore how digital forms of data are poised to illuminate the reimbursement pathway, as market access gets its closeup.
Drugmakers inconsistently share clinical trial data; AstraZeneca's share price falls after Mystic results; some pregnancy apps share info with marketers
The FDA-approved app will allow MS patients to share their medication injection history with HCPs.
As drugmakers hire economists and pharmacologists to better grapple with big data, how can ad agencies ensure they're not left behind?
Fitness trackers do not reliably track calories, docs find; health-tech startups face market uncertainty; FDA adcom votes in favor of Puma breast-cancer drug
This includes Sarepta Therapeutics' Exondys 5 and Vertex Pharmaceuticals' Orkambi.
Drugs approved through the accelerated approval pathway, as well as psychiatric drugs, were more likely to have a safety issue following FDA approval.
The market for health data and technology is growing, but the industry must also address concerns about privacy, standards, and diversity.
HHS Secretary Tom Price calls for health IT that works for clinicians and better interoperability.
QuintilesIMS partners with Salesforce; the E.U. to decide on new EMA location by June; drugmakers boost lobbying dollars in Q1
This is likely due, in part, to the increasingly complex nature of new specialty drugs.
An analysis of claims data found that an off-label settlement for one Eli Lilly drug did not significantly change how often it was prescribed off-label after the settlements.
These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.
In the wake of MD Anderson's costly failure with IBM's Watson supercomputer, a Watson backlash brewing in biopharma may lead to a moment of reckoning in life sciences.
Amy Molyneux is co-founder and EVP of Meta.
Libbe Englander is founder and CEO of Pharm3r.
Jeff Ceitlin is CCO of HVH Patient Precision Analytics.
Organizations are focusing on better ways to verify HCPs' digital identities.
Pfizer and Bristol-Myers Squibb were the top spenders last year.
Microsoft reenters healthcare market; Trump accuses Cummings of avoiding drug-pricing meeting; Trump says ACA replacement plan to be unveiled in March